SURMOUNT-5 Trial: Tirzepatide Beats Semaglutide 2.4mg Head-to-Head for Weight Loss
Medically reviewed by Dr. James Whitfield, DO, FACOI
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025 by Aronne et al., was the definitive head-to-head showdown: tirzepatide vs semaglutide 2.4mg for obesity. In 751 adults without diabetes, tirzepatide achieved 20.2% weight loss vs semaglutide's 13.7% over 72 weeks — a 47% greater reduction that settled the debate over which drug is more effective for weight management.
SURMOUNT-5: The Definitive Head-to-Head Showdown
The question that dominated obesity medicine for years — "Is tirzepatide or semaglutide better for weight loss?" — was answered definitively by the SURMOUNT-5 trial. Published in the New England Journal of Medicine in May 2025 by Aronne et al., this was the first randomized, head-to-head comparison of tirzepatide against semaglutide 2.4 mg (the full obesity dose) in adults without diabetes. The results were unequivocal: tirzepatide produced significantly greater weight loss [1].
Why This Trial Matters
Prior to SURMOUNT-5, the comparison between tirzepatide and semaglutide relied on cross-trial comparisons:
While suggestive, cross-trial comparisons are unreliable due to differences in patient populations, trial design, and measurement methods. SURMOUNT-5 eliminated these confounders with a direct, randomized comparison.
Additionally, the earlier SURPASS-2 trial compared tirzepatide against semaglutide 1 mg (the diabetes dose), not the higher 2.4 mg obesity dose. SURMOUNT-5 used the maximum approved doses of both drugs [1].
---
> Want personalized dosing and protocol guidance? The providers at Telegenix specialize in peptide therapy and TRT, designing protocols around your unique labs and health objectives. Get started with a free consultation.
---
Study Design
SURMOUNT-5 was a 72-week, open-label, randomized Phase 3b trial:
Both drugs followed their standard dose-escalation protocols:
Primary Results: Tirzepatide Wins Decisively
Mean Percent Change in Body Weight at 72 Weeks:
Tirzepatide produced 47% greater weight loss than semaglutide — a clinically enormous difference [1].
Categorical Weight Loss Thresholds
The categorical results further highlighted tirzepatide's advantage:
| Weight Loss Threshold | Tirzepatide | Semaglutide 2.4 mg |
|---|---|---|
| ≥5% | 93% | 86% |
| ≥10% | 82% | 68% |
| ≥15% | 70% | 48% |
| ≥20% | 54% | 29% |
| ≥25% | 35% | 14% |
At the ≥20% threshold — a level approaching bariatric surgery outcomes — tirzepatide nearly doubled semaglutide's success rate. More than one in three tirzepatide patients lost ≥25% of their body weight [1].
Waist Circumference
Tirzepatide also produced significantly greater reduction in waist circumference:
Waist circumference is a key indicator of visceral fat, which is more metabolically harmful than subcutaneous fat. The greater waist reduction suggests tirzepatide may preferentially reduce visceral adiposity [1].
Safety Comparison
The safety profiles were broadly similar:
Gastrointestinal Events:
Discontinuation due to adverse events:
Serious adverse events:
Notably, despite producing significantly greater weight loss, tirzepatide did not have meaningfully higher rates of adverse events. The GI side effect profiles were comparable, suggesting that the dual GIP/GLP-1 mechanism achieves greater efficacy without proportionally increasing side effects [1].
Why the 6.5% Difference Matters
A 6.5 percentage point difference in weight loss is clinically significant for several reasons:
The Dual Agonist Advantage Confirmed
SURMOUNT-5 provides the strongest evidence yet that the dual GIP/GLP-1 mechanism is superior to GLP-1 alone:
GIP's Contribution:
The consistent ~6-7 percentage point advantage of tirzepatide over semaglutide across multiple trials (SURPASS-2 for diabetes, SURMOUNT-5 for obesity) suggests this is a real and reproducible effect of the dual mechanism [2].
Clinical Decision-Making
For clinicians choosing between tirzepatide and semaglutide:
Favor Tirzepatide When:
Favor Semaglutide When:
> Related Comparison: Ozempic vs Mounjaro: Complete Comparison
References
---
> From research to results — get expert guidance. Telegenix specializes in physician-supervised peptide therapy and testosterone optimization. Schedule your free consultation and start your personalized protocol.
---
Related Reading
Explore more in-depth guides on related topics:
For a comprehensive overview, see our Complete Guide to Peptide Therapy.
---